spt-in-1

SPT-IN-1 is an inhibitor of potent serine palmitoyl transferase (SPT).

Nicotinamide-d4 is intended for use as an internal standard for the quantification of nicotinamide by GC- or LC-MS. Nicotinamide is an amide form of niacin, which is also known as vitamin B3, that can be biosynthesized in vivo or obtained through the diet. It is a precursor in the synthesis of the metabolic cofactor NAD+ and an inhibitor of sirtuin 1 (SIRT1; IC50 = <50 µM). Nicotinamide (10 µM) increases the activity of serine palmitoyltransferase (SPT) and the biosynthesis of ceramide, glucosylceramide, sphingomyelin, free fatty acids, and cholesterol in primary human keratinocytes. Nicotinamide (40 µM) induces apoptosis in SNU-398, SNU-739, and HepG2 hepatocellular carcinoma (HCC) cells, and it prevents the formation of neoplastic lesions in a diethylnitrosamine-induced mouse model of HCC. Unlike niacin, nicotinamide does not reduce plasma lipid levels or induce flushing.

SGF29-IN-1 (Compound Cpd_DC60) serves as a selective inhibitor targeting the Tudor domain of the Spt-Ada-Gcn5 acetyltransferase (SAGA)-associated factor 29 (SGF29). It has demonstrated effectiveness in treating leukemia [1].

ARN 14494 is a potent serine palmitoyltransferase inhibitor (SPT; IC50 = 27.3 nM). ARN 14494 inhibits synthesis of long chain ceramides and dihydroceramides in an in vitro model of Alzheimer's diease. The compound prevents the synthesis of proinflammatory cytokines and the oxidative stress-related enzymes iNOS and COX-2 in mouse primary cortical astrocytes. ARN 14494 is neuroprotective against β-amyloid 1-42 induced neurotoxicity in primary cortical neurons co-cultured with astrocytes.

Nicotinamide Hydrochloride, a form of vitamin B3 (niacin), inhibits sirtuin 2 (SIRT2) activity in vitro with an EC50 of 2 μM, reducing melanoma cell number by up to 90% and increasing cellular NAD+, ATP, and ROS levels. It also inhibits tumor growth in vivo and improves survival in melanoma-bearing mice, making it useful for skin cancer research, including melanoma.

Nicotinamide N-oxide (Nicotinamide 1-oxide) is recognized as an in vivo metabolite of nicotinamide which is a precurser of nicotinamide-adenine dinucleotide (NAD+) in animals. The enzyme that catalyzes the reduction of nicotinamide N-oxide to nicotinamide in the liver is xanthine oxidase.

Nicotinamide ascorbate is a bioactive chemical.